Liquidia's YUTREPIA hits $222.7M in Q3 as a $389.7M settlement charge clears the courtroom
Liquidia's net product sales rose 31% sequentially and adjusted EBITDA reached $140.5M, but the United Therapeutics settlement removes PH-ILD from YUTREPIA's label and commits cash through 2027.
The quarter in numbers
Liquidia reported net product sales of $222.7 million for the third quarter ended September 30, 2026, up 31% from the second quarter of 2026. A year earlier the figure was $51.7 million. The company attributed the $171.0 million year-over-year increase to higher YUTREPIA volume. It began shipping in the U.S. in June 2025, after full FDA approval in May 2025.
The GAAP result was a net loss of $236.3 million, or $2.64 per basic and diluted share, against a loss of $3.5 million, or $0.04 per share, in the third quarter of 2025. The gap is the $389.7 million litigation settlement charge. Excluding that charge, the company said, YUTREPIA sales produced a fifth consecutive quarter of rising non-GAAP adjusted EBITDA, which was $140.5 million. An income tax benefit of $30.1 million partly cushioned the loss; there was none in the prior-year quarter.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Sources
- Liquidia Corp: quarterly results release (SEC filing) SEC EDGAR · 10 Nov 2026
Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. Earnings analysis is based on the company's results release filed with the SEC, not on the earnings call. It can contain errors; check the sources. Not investment advice.
Tonix's TONMYA reaches $15M, but a $163M cash pile and a Paragraph IV filing frame the debate
Third-quarter net product revenue rose to about $17.2M, yet opex of $72.7M and a runway only into early Q3 2027 mean financing and patent litigation loom over the launch.
ADC Therapeutics: volume-led sales and deeper cost cuts, as recapitalisation shifts focus to ASH
Q3 net product revenue of $21.0M and a 29% cut in adjusted opex narrowed the loss, while an October restructuring extended the company's expected cash runway into 2029.
Inhibrx's Q3: Debt and launch prep push losses up as chondrosarcoma review looms
A $2.0 million Pfizer licence fee barely dented a $38.7 million net loss as interest costs and pre-commercial spend rose while R&D fell and the balance sheet moved into deficit.